What is the contribution margin and overall profitability of the NeXT Personal® platform in Q2 2025? | PSNL (Aug 06, 2025) | Candlesense
PSNL

What is the contribution margin and overall profitability of the NeXT Personal® platform in Q2 2025?

The press release you shared reports that Personalis Inc. (NASDAQ: PSNL) delivered 3,478 clinical tests in Q2 2025—a 59 % sequential increase over Q1—but it does not disclose any specific financial metrics for the NeXT Personal® platform, such as its contribution margin or overall profitability for the quarter.

What we can infer from the available information

Metric Information provided in the release
Number of clinical tests 3,478 (up 59 % vs. Q1 2025)
Revenue impact Not disclosed – the release only mentions test volume, not the associated revenue or cost figures.
Contribution margin Not disclosed – the release does not break out cost of goods sold or operating expenses attributable to the NeXT Personal® platform.
Overall profitability Not disclosed – there is no mention of gross profit, operating profit, or net profit specific to the platform.

Next steps to obtain the desired data

  1. Full earnings release – The complete Q2 2025 earnings release (often posted on Personalis’ investor‑relations website) typically includes a detailed financial table that breaks out revenue, cost of goods sold, and contribution margin by product line or platform.
  2. Form 10‑Q filing – Personalis’ quarterly report filed with the SEC will contain segment‑level financials, which may provide the contribution margin for the NeXT Personal® platform.
  3. Earnings call transcript – Management often discusses profitability drivers and margins for key platforms during the earnings call; the transcript may give quantitative or qualitative insights.

Bottom line: Based solely on the news excerpt you provided, the contribution margin and overall profitability of the NeXT Personal® platform for Q2 2025 are not disclosed. You’ll need to consult the full earnings release, SEC filings, or the accompanying earnings‑call commentary for those specific numbers.

Other Questions About This News

What is the current level of GAAP and non‑GAAP earnings per share, and how do they compare to consensus estimates? What is the net revenue growth rate year-over-year for Q2 2025 and how does it compare to analyst expectations? What is the forward-looking guidance for revenue and earnings in the next quarter and FY 2025? What were the underlying drivers of the increase in clinical test volume (e.g., new contracts, pricing changes, new product adoption)? How does the Q2 2025 cash burn and cash runway compare to prior quarters and what is the updated cash runway outlook? How does the 59% sequential increase in clinical tests compare to prior quarters and to the company's historical growth rates? How have recent macro‑economic factors (e.g., reimbursement policy changes, healthcare spending trends) impacted the outlook? What is the expected impact of potential dilution from future equity issuances or convertible debt? What technical or competitive risks could affect the sustainability of the 59% test volume growth? What is the status of the “Win‑in‑MRD” strategy and its potential impact on future market share and pricing power? Are there any regulatory approvals, FDA clearances or reimbursement updates that could affect future revenue? How does Personalis’ performance compare with other precision oncology and genomics companies (e.g., Illumina, Guardant Health, Invitae) in terms of test volume and revenue growth? What are the trends in operating expenses, R&D and SG&A, and how are they impacting profitability? What guidance does management provide regarding the timeline and scalability of the NeXT Personal® platform? What is the composition of the customer base (e.g., number of hospital/clinical partners) and its concentration risk? What are the anticipated impacts of any recent partnership or licensing agreements on future revenue and margins?